Connection

Ali Rizvi to Humans

Back to Details
This is a "connection" page, showing publications Ali Rizvi has written about Humans.
Ali Rizvi
Connection Strength
0.995
Humans
  1. Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022 11; 36(11):108336.
    View in: PubMed
    Score: 0.032
  2. Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Rev Cardiovasc Ther. 2022 Jul; 20(7):515-527.
    View in: PubMed
    Score: 0.031
  3. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022 03; 21(3):291-293.
    View in: PubMed
    Score: 0.030
  4. Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. Int J Mol Sci. 2021 Nov 15; 22(22).
    View in: PubMed
    Score: 0.030
  5. Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. Int J Mol Sci. 2021 Sep 17; 22(18).
    View in: PubMed
    Score: 0.029
  6. Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care. Medicina (Kaunas). 2021 Aug 06; 57(8).
    View in: PubMed
    Score: 0.029
  7. Diabetes and COVID-19: A Tale of 2 Pandemics. J Cardiovasc Pharmacol. 2021 07 01; 78(1):e1-e2.
    View in: PubMed
    Score: 0.029
  8. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020 08; 109:154295.
    View in: PubMed
    Score: 0.027
  9. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.
    View in: PubMed
    Score: 0.024
  10. VISUAL VIGNETTE. Endocr Pract. 2018 Dec; 24(12):1110.
    View in: PubMed
    Score: 0.024
  11. Thyroid Dysfunction in Torsades de Pointes. JAMA Intern Med. 2017 11 01; 177(11):1693.
    View in: PubMed
    Score: 0.022
  12. Giant Intracranial Aneurysm Masquerading in the Sella. Am J Med Sci. 2016 Jan; 351(1):119.
    View in: PubMed
    Score: 0.020
  13. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015; 15(10):1391-7.
    View in: PubMed
    Score: 0.019
  14. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opin Pharmacother. 2015 Feb; 16(3):281-4.
    View in: PubMed
    Score: 0.018
  15. Thyroid bruit and the underlying 'inferno'. Am J Med. 2014 Jun; 127(6):489-90.
    View in: PubMed
    Score: 0.017
  16. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.
    View in: PubMed
    Score: 0.017
  17. Gestational diabetes and the metabolic syndrome: can obesity and small, dense low density lipoproteins be key mediators of this association? Curr Pharm Biotechnol. 2014; 15(1):38-46.
    View in: PubMed
    Score: 0.017
  18. Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. Metab Syndr Relat Disord. 2014 Feb; 12(1):1-10.
    View in: PubMed
    Score: 0.017
  19. The "calcium supplement syndrome": modern-day reemergence of a bygone disorder. J S C Med Assoc. 2013 Sep; 109(3):88-91.
    View in: PubMed
    Score: 0.017
  20. Thyrotoxicosis and neck pain: getting the right test at the right time. Am J Med. 2013 Aug; 126(8):e7-8.
    View in: PubMed
    Score: 0.017
  21. Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opin Ther Targets. 2013 Jul; 17(7):739-42.
    View in: PubMed
    Score: 0.017
  22. Visual vignette. Endocr Pract. 2012 Nov-Dec; 18(6):1039.
    View in: PubMed
    Score: 0.016
  23. Visual vignette. Suppurative thyroiditis due to Nocardia asteroides. Endocr Pract. 2012 May-Jun; 18(3):426.
    View in: PubMed
    Score: 0.015
  24. Headache, pituitary lesion and panhypopituitarism in a pregnant woman: tumor, apoplexy or hypophysitis? Am J Med Sci. 2011 Sep; 342(3):247-9.
    View in: PubMed
    Score: 0.015
  25. Vitamin D deficiency in patients with congestive heart failure: mechanisms, manifestations, and management. South Med J. 2011 May; 104(5):325-30.
    View in: PubMed
    Score: 0.014
  26. Hypertension, obesity, and inflammation: the complex designs of a deadly trio. Metab Syndr Relat Disord. 2010 Aug; 8(4):287-94.
    View in: PubMed
    Score: 0.014
  27. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract. 2010 May-Jun; 16(3):441-5.
    View in: PubMed
    Score: 0.013
  28. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009 Oct; 338(4):310-8.
    View in: PubMed
    Score: 0.013
  29. Impact of comprehensive diabetes specialty care in the management of older adults with stage 3 or 4 nephropathy. South Med J. 2009 Sep; 102(9):985.
    View in: PubMed
    Score: 0.013
  30. Vitamin D levels in patients seen in the diabetes unit of an academic medical center. South Med J. 2008 Oct; 101(10):1069.
    View in: PubMed
    Score: 0.012
  31. 46, XX man with SRY gene translocation: cytogenetic characteristics, clinical features and management. Am J Med Sci. 2008 Apr; 335(4):307-9.
    View in: PubMed
    Score: 0.012
  32. "Thyrotoxic psychosis" associated with subacute thyroiditis. South Med J. 2007 Aug; 100(8):837-40.
    View in: PubMed
    Score: 0.011
  33. Care of patients with diabetes who are undergoing surgery. JAAPA. 2007 Apr; 20(4):36, 38, 41-2 passim.
    View in: PubMed
    Score: 0.011
  34. Development, implementation and preliminary results of the Diabetes Chronic Disease Management Collaborative in South Carolina. J S C Med Assoc. 2007 Apr; 103(3):54-9.
    View in: PubMed
    Score: 0.011
  35. Management of diabetes in older adults. Am J Med Sci. 2007 Jan; 333(1):35-47.
    View in: PubMed
    Score: 0.011
  36. Parasellar meningioma resembling a pituitary tumor. Endocr Pract. 2007 Jan-Feb; 13(1):86-8.
    View in: PubMed
    Score: 0.011
  37. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci. 2006 Jun; 331(6):334-5.
    View in: PubMed
    Score: 0.010
  38. Assessment and monitoring of glycemic control in primary diabetes care: monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation. J Am Acad Nurse Pract. 2006 Jan; 18(1):11-21.
    View in: PubMed
    Score: 0.010
  39. The role of inflammation in diabetes and its complications. South Med J. 2006 Jan; 99(1):8-9.
    View in: PubMed
    Score: 0.010
  40. Current trends in diabetes management. JAAPA. 2005 Aug; 18(8):23-9.
    View in: PubMed
    Score: 0.010
  41. Hypocalcemia and parathyroid function in metastatic prostate cancer. Endocr Pract. 2005 Jul-Aug; 11(4):254-8.
    View in: PubMed
    Score: 0.010
  42. Type 2 diabetes: epidemiologic trends, evolving pathogenetic [corrected] concepts, and recent changes in therapeutic approach. South Med J. 2004 Nov; 97(11):1079-87.
    View in: PubMed
    Score: 0.009
  43. Some clues and pitfalls in the diagnosis of acromegaly. Endocr Pract. 2004 Jul-Aug; 10(4):348-52.
    View in: PubMed
    Score: 0.009
  44. Recognition and implications of the metabolic syndrome. J S C Med Assoc. 2004 Apr; 100(4):107-12.
    View in: PubMed
    Score: 0.009
  45. Primary ovarian lymphoma manifesting with severe hypercalcemia. Endocr Pract. 2003 Sep-Oct; 9(5):389-93.
    View in: PubMed
    Score: 0.008
  46. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Kaunas). 2022 Oct 17; 58(10).
    View in: PubMed
    Score: 0.008
  47. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022 12 01; 1868(12):166559.
    View in: PubMed
    Score: 0.008
  48. Thiazolidinedione therapy in a patient with diabetes after cardiac transplantation. Endocr Pract. 2002 Jul-Aug; 8(4):287-91.
    View in: PubMed
    Score: 0.008
  49. The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel. Int J Mol Sci. 2022 Jun 30; 23(13).
    View in: PubMed
    Score: 0.008
  50. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina (Kaunas). 2022 Jan 11; 58(1).
    View in: PubMed
    Score: 0.008
  51. Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review. Curr Pharm Des. 2022; 28(21):1758-1768.
    View in: PubMed
    Score: 0.008
  52. Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. Metab Syndr Relat Disord. 2022 04; 20(3):137-140.
    View in: PubMed
    Score: 0.008
  53. Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice. Adv Ther. 2022 01; 39(1):1-4.
    View in: PubMed
    Score: 0.007
  54. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1):9-20.
    View in: PubMed
    Score: 0.007
  55. Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. Int J Mol Sci. 2021 Aug 29; 22(17).
    View in: PubMed
    Score: 0.007
  56. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
    View in: PubMed
    Score: 0.007
  57. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci. 2021 Jun 21; 22(12).
    View in: PubMed
    Score: 0.007
  58. Novel Therapeutical Approaches to Managing Atherosclerotic Risk. Int J Mol Sci. 2021 Apr 28; 22(9).
    View in: PubMed
    Score: 0.007
  59. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2021 08 01; 1867(8):166148.
    View in: PubMed
    Score: 0.007
  60. Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. Curr Pharm Des. 2021; 27(35):3729-3740.
    View in: PubMed
    Score: 0.007
  61. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.
    View in: PubMed
    Score: 0.007
  62. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
    View in: PubMed
    Score: 0.007
  63. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. Metab Syndr Relat Disord. 2020 05; 18(4):173-175.
    View in: PubMed
    Score: 0.007
  64. Microvascular and macrovascular effects of liraglutide. Int J Cardiol. 2019 07 01; 286:17-18.
    View in: PubMed
    Score: 0.006
  65. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Res Clin Pract. 2019 Mar; 149:163-169.
    View in: PubMed
    Score: 0.006
  66. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
    View in: PubMed
    Score: 0.006
  67. Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. Diabetes Obes Metab. 2017 05; 19(5):613-614.
    View in: PubMed
    Score: 0.005
  68. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
    View in: PubMed
    Score: 0.005
  69. Incretins, Pregnancy, and Gestational Diabetes. Curr Pharm Biotechnol. 2016; 17(7):597-602.
    View in: PubMed
    Score: 0.005
  70. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab. 2015 Feb; 100(2):603-6.
    View in: PubMed
    Score: 0.005
  71. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014 Sep; 37(9):517-22.
    View in: PubMed
    Score: 0.005
  72. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014 Feb 22; 13:49.
    View in: PubMed
    Score: 0.004
  73. Uric acid metabolism in pre-hypertension and the metabolic syndrome. Curr Vasc Pharmacol. 2014; 12(4):572-85.
    View in: PubMed
    Score: 0.004
  74. Diabetic ketoalkalosis in children and adults. South Med J. 2014 Jan; 107(1):6-10.
    View in: PubMed
    Score: 0.004
  75. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013 Dec; 166(6):1035-42.
    View in: PubMed
    Score: 0.004
  76. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013 Sep; 6(9):914-22.
    View in: PubMed
    Score: 0.004
  77. Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011. Metab Syndr Relat Disord. 2013 Dec; 11(6):417-26.
    View in: PubMed
    Score: 0.004
  78. A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19(27):4953-63.
    View in: PubMed
    Score: 0.004
  79. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013; 19(21):3858-68.
    View in: PubMed
    Score: 0.004
  80. Prevalence and impact of initial misclassification of pediatric type 1 diabetes mellitus. South Med J. 2012 Oct; 105(10):513-7.
    View in: PubMed
    Score: 0.004
  81. Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012 May 15; 8(1):87-93.
    View in: PubMed
    Score: 0.004
  82. The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly. Angiology. 2012 Oct; 63(7):492-4.
    View in: PubMed
    Score: 0.004
  83. Normocalcemic primary hyperparathyroidism-characteristics and clinical significance of an emerging entity. Am J Med Sci. 2012 Feb; 343(2):163-166.
    View in: PubMed
    Score: 0.004
  84. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 Oct; 18(10):1495-503.
    View in: PubMed
    Score: 0.003
  85. The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol. 2009 Mar; 46(1):1-11.
    View in: PubMed
    Score: 0.003
  86. A collaborative approach to the recruitment and retention of minority patients with diabetes in rural community health centers. Contemp Clin Trials. 2009 Jan; 30(1):63-70.
    View in: PubMed
    Score: 0.003
  87. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci. 2006 Mar; 331(3):154-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.